Levetiracetam Zentiva

Levetiracetam, the active ingredient in Levetiracetam Zentiva, is an anticonvulsant presented as an oral tablet for oral use. It is employed to treat various seizure types in patients diagnosed with epilepsy.

GNH USA supplies Levetiracetam Zentiva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable sourcing for regulated markets across Europe, Asia, Africa and the Americas. All shipments are accompanied by full documentation to meet local regulatory requirements.

Levetiracetam is an antiepileptic drug that reduces abnormal neuronal firing in seizure disorders.

Partial seizures: decreases frequency of focal onset seizures in patients with epilepsy. Generalized tonic‑clonic seizures: helps control convulsive episodes in patients with generalized epilepsy. Myoclonic seizures: reduces rapid muscle jerks associated with myoclonic epilepsy.

Levetiracetam may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Dizziness: transient sensation of light‑headedness. - Fatigue: feeling unusually tired or low in energy. - Somnolence: increased sleepiness during the day. - Headache: mild to moderate cranial pain. - Irritability: heightened emotional responsiveness. - Nausea: upset stomach, sometimes with mild vomiting.

Serious or Rare Side Effects: - Severe allergic reactions: including anaphylaxis. - Stevens‑Johnson syndrome or toxic epidermal necrolysis: severe skin blistering. - Suicidal thoughts or behavior: emergent mood changes. - Blood dyscrasias: neutropenia, thrombocytopenia, or anemia. - Severe skin rash: widespread erythema or exfoliation. - Hepatic failure: signs of liver dysfunction such as jaundice.

Before initiating therapy, clinicians should evaluate patient‑specific factors and monitor for potential complications. - Renal impairment: adjust dose in patients with reduced kidney function. - Hepatic impairment: monitor liver enzymes in patients with liver disease. - Pregnancy: safety not established; weigh benefits against potential risks. - Concomitant CNS depressants: monitor for enhanced sedation or respiratory depression. - Mood changes: observe for depression, aggression, or suicidal ideation. - Store at ambient temperature: keep below 25 °C, protect from moisture and light.

Levetiracetam has a relatively low interaction profile, but certain co‑medications require caution.

Major Interactions (Avoid): - Carbamazepine: may lower levetiracetam plasma concentrations. - Phenytoin: may reduce levetiracetam exposure. - Phenobarbital: may decrease levetiracetam levels.

Moderate Interactions (Monitor Closely): - Alcohol: additive central nervous system depression. - Other antiepileptic drugs (e.g., valproate): may increase risk of adverse effects. - Oral contraceptives: may experience reduced efficacy. - Antidepressants (e.g., SSRIs): monitor for mood alterations. - Antipsychotics: watch for increased sedation.